Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Σάββατο 17 Μαρτίου 2018

Surgical Resection And Adjuvant Radiation Therpy In The Treatment Of Skull Base Chordomas.

Surgical Resection And Adjuvant Radiation Therpy In The Treatment Of Skull Base Chordomas.

World Neurosurg. 2018 Mar 12;:

Authors: Sanusi OR, Arnaout O, Rahme RJ, Horbinski C, Chandler JP

Abstract
OBJECTIVE: Chordomas are rare tumors of notochordal origin that are known to be locally aggressive and are often treated with surgical resection followed by adjuvant radiotherapy. The accepted standard of treatment for chordomas of the mobile spine which includes en-bloc resection with wide margins cannot be easily applied to the chordomas of the skull base given their proximity to critical neurovascular structures. We describe our experience with the role of surgery and adjuvant radiation in the treatment of chordomas over 16 years.
MATERIALS AND METHODS: We performed a retrospective chart review on patients diagnosed with clival chordoma between the years 2000 and 2015 at Northwestern Memorial Hospital. We reviewed presenting symptoms, tumor location and size, extent of resection, complications, recurrence, adjuvant treatment, and follow-up duration.
RESULTS: A total of 20 patients underwent 32 surgeries. Of the 20 initial surgeries, 80% underwent gross total resection (GTR) while 20% had subtotal resection (STR). The mean follow-up was 60.75 months. Mean tumor volume was 23.07 cm3. Most common presenting signs and symptoms were headaches (70%), cranial nerve palsies (45%) and diplopia (55%). Diplopia was defined as patients with complaints of double vision without any objective evidence of a cranial nerve palsy. Median time to progression was 57 months and median overall survival was 136 months. Initial tumor volume and the need for a second dose of radiation either as sole or adjuvant treatment of a recurrence had a statistically significant effect on progression free survival (p= 0.009, 0.009). None of the factors studied had a statistically significant effect on overall survival.
CONCLUSION: The treatment of chordomas remain challenging and requires multi-modal treatment strategies spanning different specialties. Initial tumor size and need for second dose of radiation therapy for recurrence appear to play a significant role in progression-free survival. Adjuvant radiation after gross total resection may play a role in improved progression-free and overall survival in patients with clival chordomas.

PMID: 29545225 [PubMed - as supplied by publisher]



http://ift.tt/2IvSAQD

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου